VENICE, Fla., Aug. 19 SinoFresh HealthCare,Inc., (OTC Bulletin Board: SFSH) announced preliminary results today from asuccessful in vivo pilot study indicating that its patented SinoFresh(R) nasalspray was shown to be useful in controlling the MRSA "super-bug" in the nasalpassages. This study utilized a recognized scientific model intended todemonstrate SinoFresh(R) nasal spray's ability to kill MRSA hiding in thenasal passages. These favorable efficacy results follow an earlier, successfulin vitro study that was conducted at the Public Health Research Instituteunder the direction of Dr. Barry Kreiswirth, director of the TuberculosisCenter and Hospital Infections Program.
The study showed that "SinoFresh(R) nasal spray used three times dailyappeared to effectively eliminate MRSA in the noses of the test animals whileleaving enough normal microbes to keep a normal population in the nasalpassages," according to Dr. John Todhunter, consultant to SinoFresh, whooversaw the study conducted at Virion Systems in Rockville, MD.
MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is agrowing concern in the health care community. It incubates in the nasalpassages and then gets on the skin where it can cause severe, virulentinfections. The effect of MRSA can lead to disfigurement and sometimes death.MRSA is also highly antibiotic resistant, making MRSA infections difficult totreat. It is believed that approximately 2 - 3 million persons in the U.S.walk around carrying MRSA in their nasal passages at any time and eliminationor severe reduction of nasal MRSA colonies is seen as a potentially importantweapon in fighting the spread of MSRA. The antibiotic Mupirocin is currentlyused to reduce nasal MRSA loads.
SinoFresh(R) nasal spray attacks MRSA in the nasal passages by destroyingthe "super-bug's" cell walls and membranes by physical means rather than by anantibiotic mechanism involving attack on the metabolism of the microbes asoccurs with the use of antibiotics. "Since bacteria can in effect change theirmetabolism to be resistant to antibiotics, but can't very well change the lawsof physics the chances for development of resistance to SinoFresh(R) NasalSpray's mode of killing them is much lower said Dr. Todhunter."
According to William Wilferth, VP for Research and Development atSinoFresh, "These results have exceeded our expectations. The positive resultsof this in vivo study gives us the solid scientific platform we have needed inorder to advance our efforts to fight MRSA to the next level."
Charles Fust, CEO of SinoFresh, noted that the data reported is extremelyencouraging and that there is a significant market need for new methods toaddress MRSA control which is believed to be as many as 80 to 100 milliontreatments annually in the United States alone.
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer andmarketer of innovative upper respiratory system therapies. The company isresearching broad-spectrum antiseptic approaches to reducing viral, bacterialand fungal organisms that are suspected to cause pathogenesis of the mouth,nose and throat. The company's lead product, SinoFresh(R) Nasal and SinusCare, is a hygienic cleansing spray that kills germs and removes othernasal-sinus irritants. The company is also researching how antisepticcleansing may alleviate chronic sinus distress, a condition that may affect 37million Americans annually. SinoFresh(R) products are available in majorretail outlets nationwide. More information is available athttp://www.sinofresh.com.Contact: William Wilferth, R. Ph. M.S. VP Research & Development SinoFresh HealthCare, Inc. 787 Commerce Drive / Suite 6 Venice, FL 34292 Tel: (941) 488-9090 / e-mail: firstname.lastname@example.org
SOURCE SinoFresh HealthCare, Inc.